Rx Coupon Stakeholders Seek Clarity On Use In Exchanges
This article was originally published in The Pink Sheet Daily
Executive Summary
Letters from patient advocacy organizations express confusion over recent government statements on the use of patient assistance programs in the state insurance marketplaces. Drug manufacturers are also anxious for more definitive guidance.
You may also be interested in...
J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.